• Immunocore reported KIMMTRAK net sales of $325 million for January-September 2026, up 10% year over year.
• The Phase 3 TEBE-AM cutaneous melanoma trial completed target enrollment of 540 patients; topline data are expected in second-quarter 2027.
• KIMMTRAK combined with brenetafusp produced a 29% response rate in 17 previously untreated metastatic uveal melanoma patients.
• Overall survival rates for the combination reached 88% at one year and 70% at two years.
• A randomized Phase 2/3 DUET-UVEAL trial is planned to evaluate the combination in metastatic uveal melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.